



An efficient total synthesis of (+)-Cladospolide C

Ch. Raji Reddy*, N. Narsimha Rao

Organic Division-I, Indian Institute of Chemical Technology, Hyderabad 500 007, India

ARTICLE INFO

Article history:

Received 5 February 2009

Revised 27 February 2009

Accepted 5 March 2009

Available online 13 March 2009

Keywords:

Cladospolide

Alkyne zipper reaction

Ynoate isomerization

Sharpless asymmetric dihydroxylation

Yamaguchi macrolactonization

ABSTRACT

The asymmetric synthesis of (+)-Cladospolide C has been achieved in 11 steps with 26% overall yield. Key steps in the sequence involve KAPA-promoted alkyne Zipper reaction, TPP-promoted enyne ester (ynoate) to diene ester (dienoate) isomerization, Sharpless asymmetric dihydroxylation and Yamaguchi macrolactonization.

© 2009 Elsevier Ltd. All rights reserved.

Cladospolide C (**1**), a 12-membered macrolide was isolated in 1995 by Fukuda and co-workers from a culture filtrate of the fungus, *Cladosporium tenuissimum*¹ along with the already known Cladospolide A (**2**) and Cladospolide B (**3**, Fig. 1). These 12-membered macrolides are plant growth regulators and have been shown to inhibit shoot elongation in rice seedlings.^{2–5} The biological properties of Cladospolide C suggest the inhibition of gibberellin synthesis.¹ The biological activity and structure of these macrolides have attracted the interest of organic chemists and various research groups have reported total synthesis of Cladospolide A and B.^{6,7} However, there are only four reports on the total synthesis of Cladospolide C.^{8–11} Herein, we report an efficient asymmetric synthesis of (+)-Cladospolide C in high yield compared to the earlier reported methods.

The synthesis commenced with the (*R*)-propylene oxide **4**, which was treated with the lithiated 1-octyne to afford alkynol **5** in 89% yield. The alkynol **5** was subjected to potassium 3-amino-propylamide (KAPA)-mediated alkyne zipper reaction,¹² in which alkyne functionality moves from the centre to the terminus of a chain to give the alkyne **6** in 80% yield. The hydroxyl group of compound **6** was then protected as *tert*-butyl dimethylsilyl ether **7** (TBDMSCl, imidazole, 95% yield). In the next step, the carboxylation of terminal alkyne was carried out using *n*-butyl lithium and ethyl chloroformate to obtain alkyne ester **8** in 98% yield. With the alkyne ester **8** in hand, the stage was set for the formation of the diene ester under the Rychnovsky modified condition of the Trost isomerization.¹³ Thus, the ynoate **8**, exposed to $\text{Ph}_3\text{P}/\text{PhOH}$

in benzene at room temperature for 12 h led to the clean formation of diene ester **9** in 93% yield. The dienolate **9** was treated under enantio- and regio-selective Sharpless asymmetric dihydroxylation¹⁴ conditions using AD-mix- β to give a diol **10** in 82% yield, which was treated with 2,2-dimethoxypropane in presence of catalytic amount of camphor sulfonic acid to afford **11** in 87% yield. To set the stage for Yamaguchi macrolactonization, the compound **11** was subjected to ester hydrolysis (LiOH, THF/H₂O, 96% yield) followed by desilylation (TBAF, THF, 85% yield) reaction to provide the hydroxyl acid **13**. Macrolactonization of **13** using Yamaguchi conditions gave the lactone **14** in 86% yield¹⁵ which on exposure to titanium tetrachloride for the cleavage of acetonide furnished the Cladospolide C **1** in 85% yield (Scheme 1).¹⁶ The physical





Figure 1.

* Corresponding author. Tel.: +91 40 27193434; fax: +91 40 27160512.

E-mail address: rajireddy@iict.res.in (Ch. Raji Reddy).



Scheme 1. Reagents and conditions: (a) 1-octyne, *n*-BuLi, THF, HMPA, -40°C to 0°C to -20°C , 16 h, 89%; (b) KH, 1,3-diaminopropane, rt, 3 h, 80%; (c) TBDMSCl, imidazole, DMF, 0°C to rt, 2 h, 95%; (d) ethyl chloroformate, *n*-BuLi, -78°C , 1 h, 98%; (e) PPh₃, PhOH, benzene, 12 h, 93%; (f) AD-mix- β , MeSO₂NH₂, *t*-BuOH/H₂O, 0°C , 24 h, 82%; (g) 2,2-DMP, CSA (cat.), CH₂Cl₂, 1 h, 87%; (h) LiOH, THF/H₂O, rt, 12 h, 96%; (i) TBAF, THF, rt, 24 h, 85%; (j) 2,4,6-trichlorobenzoyl chloride, DIPEA, THF, DMAP, benzene, reflux, 10 h, 85%; (k) TiCl₄, CH₂Cl₂, 0°C , 1 h, 86%.

(mp, specific rotation) and spectroscopic data (¹H NMR, ¹³C NMR, IR and MS) of the obtained target molecule were in full agreement with the reported natural product data. The specific rotation of the synthetic Cladospolide C, (+58.0, *c* 0.45, MeOH), was comparable with the natural product (+59.7, *c* 0.4, MeOH).¹

In conclusion, an efficient synthesis of 12-membered macrolide (+)-Cladospolide C has been achieved using alkyne zipper reaction, ynoate to dienoate isomerization, Sharpless asymmetric dihydroxylation and Yamaguchi macrolactonization as the key steps. The chemistry described here offers a high yielding strategy (26% overall yield), which has potential for application to the synthesis of other stereoisomers and analogues of Cladospolide C.

Acknowledgement

N.N.R. thanks CSIR, New Delhi, for the award of research fellowship.

References and notes

- Fujii, Y.; Fukuda, A.; Hamasaki, T.; Ichimoto, I.; Nakajima, H. *Phytochemistry* **1995**, *40*, 1443.
- Dai, H.-Q.; Kang, Q.-J.; Li, G.-H.; Shen, Y.-M. *Helv. Chim. Acta* **2006**, *89*, 527.
- Jaduco, R.; Proksch, P.; Wray, V.; Sudarsono, A. B.; Graefe, U. *J. Nat. Prod.* **2001**, *64*, 527.
- Smith, C. J.; Abbanat, D.; Bernan, V. S.; Maiese, W. M.; Greenstein, M.; Jompa, J.; Tahir, A.; Ireland, C. M. *J. Nat. Prod.* **2000**, *63*, 142.
- (a) Hirota, H.; Hirota, A.; Sakai, H.; Isogai, A.; Takahashi, T. *Bull. Chem. Soc. Jpn.* **1985**, *58*, 2147; (b) Hirota, A.; Sakai, H.; Isogai, A. *Agric. Biol. Chem.* **1985**, *49*, 731; (c) Hirota, A.; Sakai, H.; Isogai, A. *Agric. Biol. Chem.* **1981**, *45*, 799.
- Synthesis of Cladospolide A: (a) Banwell, M. G.; Loong, D. T. J. *Org. Biomol. Chem.* **2004**, *2*, 2050; (b) Banwell, M. G.; Jolliffe, K. A.; Loong, D. T. J.; Mcrae, K. J.; Vounatsos, F. J. *Chem. Soc., Perkin Trans. 1* **2002**, *22*; (c) Solladai, G.; Almario, A. *Tetrahedron: Asymmetry* **1995**, *6*, 559; (d) Solladai, G.; Antonio, A. *Pure Appl. Chem.* **1994**, *66*, 2159; (e) Ichimoto, I.; Sato, M.; Karihata, M.; Ueda, H. *Chem. Exp.* **1987**, *2*, 295; (f) Maemoto, S.; Mori, K. *Chem. Lett.* **1987**, 109; (g) Maemoto, S.; Mori, K. *Liebigs Ann. Chem.* **1987**, 863.
- Synthesis of Cladospolide B: (a) Pandey, S. K.; Kumar, P. *Tetrahedron Lett.* **2005**, *46*, 6625; (b) Austin, K. A. B.; Banwell, M. G.; Loong, D. T. J.; Rae, A. D.; Willis, A. C. *Org. Biomol. Chem.* **2005**, *3*, 1081.
- Chin-Yi, C.; Duen-Ren, H. *J. Org. Chem.* **2006**, *71*, 9887.
- Banwell, M. G.; Loong, D. T. J.; Willis, A. C. *Aust. J. Chem.* **2005**, *58*, 511.
- Sharma, G. V. M.; Reddy, K. L.; Reddy, J. J. *Tetrahedron Lett.* **2006**, *47*, 6537.
- While this manuscript was under review, a similar strategy has been reported for the synthesis of Cladospolide C using different starting materials, see Ref.: Xing, Y.; O'Doherty, G. A. *Org. Lett.* **2009**, *11*, 1107.
- (a) Brown, C. A.; Yamashita, A. *J. Am. Chem. Soc.* **1975**, *97*, 891; (b) Kimmel, T.; Becker, D. *J. Org. Chem.* **1984**, *49*, 2494.
- (a) Rychnovsky, S. D.; Kim, J. *J. Org. Chem.* **1994**, *59*, 2659; (b) Trost, B. M.; Kazmaier, U. *J. Am. Chem. Soc.* **1992**, *114*, 7933.
- Xu, D.; Crispino, G. A.; Sharpless, K. B. *J. Am. Chem. Soc.* **1992**, *114*, 7570.
- Inanaga, J.; Hirata, K.; Sacki, H.; Hatsuki, T.; Yamaguchi, M. *Bull. Chem. Soc. Jpn.* **1979**, *52*, 1989.
- Spectral data of new compounds: (R)-undec-3-yn-2-ol (5)*: [α]_D²⁷ -11.6 (c 1.0, CHCl₃); IR (KBr): ν_{max} 3508, 2923, 2855, 1465, 901 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 3.84 (sextet, *J* = 6.5 Hz, 1H), 2.36–2.19 (m, 2H), 2.15 (tt, *J* = 7.3, 2.2 Hz, 2H), 1.80 (br s, OH), 1.53–1.29 (m, 8H), 1.21 (d, *J* = 5.8 Hz, 3H), 0.90 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 83.0, 76.0, 66.4, 31.2, 29.2, 28.8, 28.4, 22.4, 22.0, 18.6, 13.9; MS (ESI): *m/z* 169.0 (M+H)⁺. *(R)-Undec-10-yn-2-ol (6)*: [α]_D²⁷ -6 (c 1.0, CHCl₃); IR (KBr): ν_{max} 3737, 3416, 2926, 2858, 2354, 1630, 1088, 830 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 3.80–3.70 (m, 1H), 2.16 (td, *J* = 7.0, 2.6 Hz, 2H), 1.84 (t, *J* = 2.6 Hz, 1H), 1.57–1.23 (m, 12H), 1.17 (d, *J* = 6.2 Hz, 3H); ¹³C NMR (CDCl₃, 75 MHz): δ 84.6, 68.1, 68.0, 39.2, 29.4, 29.0, 28.6, 28.4, 25.6, 23.4, 18.0. *(R)-tert-Butyldimethyl(undec-10yn-2-yloxy)silane (7)*: [α]_D²⁷ -8 (c 1.0, CHCl₃); IR (KBr): ν_{max} 3508, 3312, 2932, 2858, 2219, 1462, 1251, 833 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 3.80–3.70 (m, 1H), 2.16 (td, *J* = 6.8, 2.6 Hz, 2H), 1.81 (t, *J* = 2.6 Hz, 1H), 1.58–1.25 (m, 12H), 1.10 (d, *J* = 6.0 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 6H); ¹³C NMR (CDCl₃, 75 MHz): δ 84.6, 68.6, 68.0, 39.7, 29.5, 29.1, 28.7, 28.5, 25.9, 25.7, 23.8, 18.4, -4.4 , -4.7 ; HRMS: calcd for C₁₈H₃₃OSi (M+H)⁺: 281.2480, found: 281.2486. *(R)-Ethyl-11-(tert-butyldimethylsilyloxy)dodec-2-ynoate (8)*: [α]_D²⁸ -5 (c 1.0, CHCl₃); IR (KBr): ν_{max} 2929, 2856, 2235, 1712, 1464, 1252, 1073 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 4.2 (q, *J* = 7.2 Hz, 2H), 3.80–3.68 (m, 1H), 2.32 (t, *J* = 7.0 Hz, 2H), 1.65–1.53 (m, 2H), 1.46–1.22 (m, 13H), 1.11 (d, *J* = 6.0, 3H), 0.88 (s, 9H), 0.04 (s, 6H); ¹³C NMR (CDCl₃, 75 MHz): δ 153.8, 89.3, 73.1, 68.5, 61.7, 39.6, 29.4, 29.0, 28.7, 27.5, 25.8, 25.6, 23.8, 18.6, 18.0, 14.0, -4.4 , -4.7 ; MS (ESI): *m/z* 355.1 (M+H)⁺. *(R,2E,4E)-Ethyl-11-(tert-butyldimethylsilyloxy)dodecan-2,4-dienoate (9)*: [α]_D²⁸ -4.7 (c 1.0, CHCl₃); IR (KBr): ν_{max} 2931, 2858, 1774, 1717, 1642, 1463, 1257, 1173, 836 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.2 (dd, *J* = 15.4, 10.3 Hz, 1H), 6.19–6.04 (m, 2H), 5.73 (d, *J* = 15.4 Hz, 1H), 4.20 (q, *J* = 7.2 Hz, 2H), 3.80–3.70 (m, 1H), 2.17 (q, *J* = 6.6 Hz, 2H), 1.49–1.21 (m, 11H), 1.1 (d, *J* = 6.0 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 6H); ¹³C NMR (CDCl₃, 75 MHz): δ 167.2, 145.0, 144.5, 128.3, 119.1, 68.5, 60.0, 39.5, 32.9, 29.2, 28.6, 25.8, 25.6, 25.4, 23.7, 14.2, -4.4 , -4.7 ; HRMS: calcd for C₂₀H₃₉O₃Si (M+H)⁺: 355.2668, found: 355.2663. *(4R,5R,11R,E)-Ethyl-11-(tert-butyldimethylsilyloxy)4,5-dihydroxydodec-2-enoate (10)*: [α]_D²⁵ $+12$ (c 1.0, CHCl₃); IR (KBr): ν_{max} 3395, 2931, 2858, 1709, 1656, 1270, 1040 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 6.89 (dd, *J* = 15.6, 4.9 Hz, 1H), 6.09 (dd, *J* = 15.6, 1.7 Hz, 1H), 4.20 (q, *J* = 7.2 Hz, 2H), 4.13–4.03 (m, 1H), 3.80–3.69 (m, 1H), 3.56–3.46 (m, 1H), 2.59 (br s, 1H), 2.27 (br s, 1H), 1.30 (t, *J* = 7.2 Hz, 3H), 1.64–1.22 (m, 10H), 1.10 (d, *J* = 6.0 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 6H); ¹³C NMR (CDCl₃, 75 MHz): δ 166.5, 147.3, 122.1, 74.0, 73.9, 68.5, 60.5, 39.5, 32.9, 29.6, 25.8, 25.7, 25.6, 23.7, 18.0, 14.1, -4.4 , -4.7 ; HRMS: calcd for C₂₀H₄₁O₅Si (M+H)⁺: 389.2726, found: 389.2718. *(E)-Ethyl-3-((4R,5R)-5-((R)-6-(tert-butyldimethylsilyloxy)heptyl)-2,2-dimethyl-1,3-dioxolan-4-yl)acrylate (11)*: [α]_D²⁷ $+4.5$ (c 1.0, CHCl₃); IR (KBr): ν_{max} 3432, 2931, 2858, 1720, 1658, 1372, 1256 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 6.81 (dd, *J* = 15.6, 5.7 Hz, 1H), 6.06 (dd, *J* = 15.6, 1.3 Hz, 1H), 4.20 (q, *J* = 7.2 Hz, 2H), 4.12–4.05 (m, 1H), 3.80–3.63 (m, 2H), 1.30 (t, *J* = 7.2 Hz, 3H), 1.62–1.24 (m, 16H), 1.10 (d, *J* = 6.0 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 6H); ¹³C NMR (CDCl₃, 75 MHz): δ 165.9, 144.1, 122.6, 109.2, 80.5, 80.2, 68.5, 60.5, 39.5, 32.0, 29.7,

27.2, 26.6, 25.8, 25.6, 23.8, 18.14, 14.2, –4.4, –4.7; HRMS: calcd for $C_{23}H_{44}NaO_5Si$ ($M+Na$)⁺: 451.2862, found: 451.2850. (*E*)-3-((4*R*,5*R*)-5-((*R*)-6-(*tert*-Butyldimethylsilyloxy) heptyl)-2,2-dimethyl-1,3-dioxolan-4-yl)acrylic acid (**12**): $[\alpha]_D^{26} +3.5$ (c 1.0, $CHCl_3$); IR (KBr): ν_{max} 3438, 2931, 2858, 1702, 1658, 1374, 1250 cm^{-1} ; 1H NMR ($CDCl_3$, 400 MHz): δ 6.94 (dd, $J = 15.4$, 5.2 Hz, 1H), 6.10 (d, $J = 15.4$, 1H), 4.15–4.10 (m, 1H), 3.81–3.73 (m, 1H), 3.72–3.66 (m, 1H), 1.63–1.24 (m, 16H), 1.10 (d, $J = 6.0$ Hz, 3H), 0.88 (s, 9H), 0.04 (s, 6H); ^{13}C NMR ($CDCl_3$, 75 MHz): δ 171.0, 146.8, 121.7, 109.5, 80.5, 80.1, 65.6, 39.6, 32.1, 29.7, 29.2, 26.6, 25.9, 25.6, 23.8, 18.1, –4.4, –4.7; MS (ESI): m/z 399.1 ($M+H$)⁺. (*E*)-3-((4*R*,5*R*)-5-((*R*)-6-Hydroxyheptyl)-2,2-dimethyl-1,3-dioxolan-4-yl)acrylic acid (**13**): $[\alpha]_D^{27} +8$ (c 1.0, $CHCl_3$); IR (KBr): ν_{max} 3446, 2922, 2852, 1706, 1643, 1461, 1260, 1168, 768 cm^{-1} ; 1H NMR ($CDCl_3$, 300 MHz): δ 6.94 (dd, $J = 15.4$,

5.3 Hz, 1H), 6.10 (dd, $J = 15.4$, 1.1 Hz, 1H), 4.18–4.10 (m, 1H), 3.84–3.66 (m, 2H), 1.64–1.24 (m, 16H), 1.19 (d, $J = 6.0$ Hz, 3H); ^{13}C NMR ($CDCl_3$, 75 MHz): δ 169.3, 145.6, 122.3, 109.3, 80.4, 79.9, 68.0, 38.7, 31.8, 29.3, 27.0, 26.4, 25.7, 25.3, 22.9; HRMS: calcd for $C_{15}H_{25}O_5$ ($M-H$)⁺: 285.1701, found: 285.1710. (3*aR*,8*R*,13*aR*,*E*)-2,2,8-Trimethyl-9,10,11,12,13,13*a*-hexahydro-3*aH*-[1,3]dioxolo-[4,5-*e*]11oxacyclododecin-6(8*H*)-one (**14**):⁸ $[\alpha]_D^{26} +10.5$ (c 1.0, $CHCl_3$); 1H NMR ($CDCl_3$, 300 MHz): δ 6.78 (dd, $J = 15.8$, 9.5 Hz, 1H), 6.23 (d, $J = 15.8$ Hz, 1H), 5.05–4.93 (m, 1H), 4.04 (dd, $J = 9.3$, 8.5 Hz, 1H), 3.90 (ddd, $J = 11.0$, 8.3, 4.2 Hz, 1H), 2.10–1.90 (m, 1H), 1.70–1.50 (m, 3H), 1.48–1.35 (m, 8H), 1.30 (d, $J = 6.4$ Hz, 3H), 1.26–1.15 (m, 3H); ^{13}C NMR ($CDCl_3$, 75 MHz): δ 166.6, 143.8, 125.9, 109.2, 80.3, 80.0, 75.3, 35.3, 29.7, 27.8, 27.2, 26.8, 25.1, 24.9, 20.6; MS (ESI): m/z 269.1 ($M+H$)⁺.